MedTrace Logo

Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin

NCT00287664 · Status: SUSPENDED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2007-04-11

No results posted yet for this study

Summary

Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents (Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous studies are pilot studies and they are not able to give information about an improvement in survival. This comparative randomized study was delineated to test the efficacy of terlipressin on survival.

Conditions

  • Cirrhosis
  • Hepatorenal Syndrome

Interventions

DRUG

terlipressin

Sponsors & Collaborators

  • Grant from Education Ministery from 2001-2004.

    collaborator UNKNOWN

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Pere Gines, MD · Chair of Liver Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Completion
2006-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00287664 on ClinicalTrials.gov